Insider Trading Alert - MFRM, MDAS And MSFT Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, May 2, 2014, 147 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $416.76 to $333,500,000.00.

Highlighted Stocks Traded by Insiders:

Mattress Firm (MFRM) - FREE Research Report

Fendrich Stephen G., who is Chief Strategy Officer at Mattress Firm, sold 2,500 shares at $44.86 on May 2, 2014. Following this transaction, the Chief Strategy Officer owned 211,235 shares meaning that the stake was reduced by 1.17% with the 2,500-share transaction.

The shares most recently traded at $46.01, up $1.15, or 2.49% since the insider transaction. Historical insider transactions for Mattress Firm go as follows:

  • 4-Week # shares sold: 833
  • 12-Week # shares sold: 23,999
  • 24-Week # shares sold: 46,665

The average volume for Mattress Firm has been 229,900 shares per day over the past 30 days. Mattress Firm has a market cap of $1.5 billion and is part of the services sector and specialty retail industry. Shares are up 5.41% year-to-date as of the close of trading on Wednesday.

Mattress Firm Holding Corp., through its subsidiaries, operates as a specialty retailer of mattresses, and related products and accessories in the United States. The company has a P/E ratio of 28.8. Currently, there are 6 analysts who rate Mattress Firm a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MFRM - FREE

TheStreet Quant Ratings rates Mattress Firm as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, growth in earnings per share and good cash flow from operations. However, as a counter to these strengths, we find that the company has favored debt over equity in the management of its balance sheet. Get the full Mattress Firm Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

MedAssets (MDAS) - FREE Research Report

Wise R Halsey, who is Director at MedAssets, bought 8,950 shares at $22.31 on May 2, 2014. Following this transaction, the Director owned 8,950 shares meaning that the stake was reduced by 100% with the 8,950-share transaction.

The shares most recently traded at $22.16, down $0.15, or 0.68% since the insider transaction. Historical insider transactions for MedAssets go as follows:

  • 4-Week # shares sold: 40,000
  • 12-Week # shares sold: 41,802
  • 24-Week # shares sold: 82,109

The average volume for MedAssets has been 568,900 shares per day over the past 30 days. MedAssets has a market cap of $1.4 billion and is part of the technology sector and computer software & services industry. Shares are up 18.1% year-to-date as of the close of trading on Wednesday.

MedAssets, Inc., a financial and performance improvement company, provides technology-enabled products and services for hospitals, health systems, and other ancillary healthcare providers in the United States. The company has a P/E ratio of 57.2. Currently, there are 12 analysts who rate MedAssets a buy, 1 analyst rates it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MDAS - FREE

TheStreet Quant Ratings rates MedAssets as a buy. The company's strengths can be seen in multiple areas, such as its reasonable valuation levels, good cash flow from operations, solid stock price performance, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full MedAssets Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Microsoft (MSFT) - FREE Research Report

Gates William H Iii, who is Director at Microsoft, sold 4.6 million shares at $40.34 on May 2, 2014. Following this transaction, the Director owned 330.1 million shares meaning that the stake was reduced by 1.37% with the 4.6 million-share transaction.

The shares most recently traded at $40.00, down $0.34, or 0.84% since the insider transaction. Historical insider transactions for Microsoft go as follows:

  • 4-Week # shares sold: 3.3 million
  • 12-Week # shares sold: 23.3 million
  • 24-Week # shares sold: 23.3 million

The average volume for Microsoft has been 36.8 million shares per day over the past 30 days. Microsoft has a market cap of $334.6 billion and is part of the technology sector and computer software & services industry. Shares are up 8.29% year-to-date as of the close of trading on Wednesday.

Microsoft Corporation develops, licenses, and supports software, services, and hardware devices. Its Windows division offers Windows operating system; Windows Services suite of applications and Web services, including Outlook.com and SkyDrive; Surface RT and Pro devices; and PC accessories. The stock currently has a dividend yield of 2.83%. The company has a P/E ratio of 14.7. Currently, there are 10 analysts who rate Microsoft a buy, 1 analyst rates it a sell, and 14 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MSFT - FREE

TheStreet Quant Ratings rates Microsoft as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels, solid stock price performance and good cash flow from operations. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Microsoft Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
null

If you liked this article you might like

The CEO That Leads the King of Foam Mattresses Wants to Run the Business 'Sloppy' for a Little While

The CEO That Leads the King of Foam Mattresses Wants to Run the Business 'Sloppy' for a Little While

How to Trade Monday's Most Active Stocks -- Rite Aid, BofA, Fitbit, More

How to Trade Monday's Most Active Stocks -- Rite Aid, BofA, Fitbit, More

Mattress Firm Posts Earnings and Revenue Below Analysts' Estimates

Mattress Firm Posts Earnings and Revenue Below Analysts' Estimates

Jim Cramer: Mattress Firm's Sale Part of Bigger Furniture Trend

Jim Cramer: Mattress Firm's Sale Part of Bigger Furniture Trend